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Summary 
The putative factors that couple the signal transduction from surface receptors to the activation 
of cytokine synthesis in natural killer (NK) cells have not been elucidated. We report here that 
the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regu- 
lates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes 
in human NK cells. CD16 (FcTRIIIA)-induced expression of cytokine mRNA in NK cells occurs 
via a CsA-sensitive and Ca  2+-dependent mechanism. Stimulation of NK cells with CD16 ligands 
induces NFAT-Iike DNA binding activity in the nuclear extracts  from these cells, as detected 
in electrophoretic mobility shift assays. This occurs with fast kinetics after stimulation, via a 
CsA-sensitive and CaZ+-dependent mechanism that does not require de novo protein synthesis. 
NK cell NFAT is present in the cytosol of nonstimulated cells, migrates to the nucleus upon 
stimulation, and can associate with AP-1. Two distinct molecules, NFATp and NFATc, have been 
reported to mediate NFAT activity.  The results of supershift assays using NFATp- and NFATc- 
specific antibodies indicate that NK cell activation early after CD16 ligand binding involves primarily, 
if not exclusively, NFATp, and Western blot analysis shows that this has the same electrophoretic 
mobility ('~120 kD) as that of T lymphocytes. NK cells do not express NFATc constitutively, 
but NFATc mRNA accumulation is induced in these cells within 2 h of stimulation with CD16 
ligands. However, supershift assays using the available mAb recognizing the T  cell NFATc re- 
vealed no detectable NFATc protein in nuclear and cytoplasmic extracts from CD16- or phorbol 
ester-stimulated cells at any time tested, up to 4 h. These results provide the first direct evidence 
that both CsA-sensitive transcription factors, NFATp and NFATc, are expressed in human NK 
cells, and that their activation and/or expression  can be regulated in primary cells by a single 
stimulus that, in the case of CD16 in NK cells, results in early activation of NFATp and subse- 
quently induced expression of NFATc mRNA. 
N 
'K cells play an important role in the early phases of an 
immune response, mediating cytotoxicity against num- 
erous target cells in the absence of previous sensitization,  and 
producing cytokines (IFN-% TNF, GM-CSF, and IL,3). Both 
functions are triggered or enhanced upon stimulation with 
target  cells,  immune complexes,  and  lymphokines, each 
binding to different receptors (reviewed in references 1-3). 
The proximal intracelhlar events induced upon ligand binding 
to the transmembrane form of the low affinity receptor for 
IgG (CD16, Fc3,RIIIA)  1 on NK cells are being elucidated 
(4-8),  but no information is available on the distal  events 
1Abbreviations used in  this paper: Act  D,  actinomycin  D;  ~2M,  32 
microglobulin; [Ca2+]i, intraceUular Ca  2+ concentration;  CsA, cyclosporin 
A; E, erythrocytes; EA, Ab-coated erythrocytes; EMSA, electrophoretic 
mobility shift assay; Fc'yR, receptor for the Fc fragment of IgG; NFAT, 
nuclear factor of activated T cells; NRS, nonimmune rabbit serum; PDBu, 
phorbol-12, 13-dibutyrate;  PKC, protein kinase C. 
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of cytokine genes transcription  in these cells. 
CD16-induced production of cytokines (e.g.,  IFN-3, and 
TNF), but not that of CD25 or other proteins involved in 
cytotoxicity (8-10), depends on increased intracellular Ca  2+ 
concentration ([Ca2+]i) after extracellular Ca  2+ entrance (8). 
In T  lymphocytes, the TCR-induced increase  of [Ca2+]i is 
also  a requisite  for  the  expression  of several  lymphokines 
(reviewed in reference 11), and a pathway has been elucidated 
which  connects  the  [Ca~+]i increase  to  the  regulation  of 
cytokine  transcription  via  activation  of  the  cytoplasmic 
serine/threonine phosphatase calcineurin  A and its subsequent 
effect on the transcription nuclear factor of activated T cells 
(NFAT) (11-15).  NFAT is present in the cytoplasm of non- 
stimulated cells as a phosphoprotein, NFATp, which, dephos- 
phorylated upon cellular stimulation, migrates into the nuc- 
leus, where it binds specific DNA sequences in the promoter/ 
enhancer  regions of cytokine genes (reviewed in references 
11 and  16-20). 
Originally described as a cyclosporin A (CsA)-sensitive factor 
binding the II.,2 promoter (21-23), NFAT also binds NFAT- 
specific sites in the promoters of other cytokines (Ib3, IL-4, 
TNF-oL,  and GM-CSF) (17,  19, 20,  24, 25), where it may 
cooperate with other factors, e.g., AP-1 (IIr  II-3, and GM- 
CSF promoters) (12, 17, 25). These observations indicate that 
its activity is not restricted to the regulation of the IL-2 gene. 
The  distribution  of NFAT  extends  beyond TH1  lympho- 
cytes: NFATp is transcriptionally  active in B cells  (26, 27), 
where it likely regulates expression of TNF (19, 28). At least 
two related but distinct  NFAT proteins  exist,  NFATp  and 
NFATc, that have identical binding specificity and activation 
requirements  (29, 30), and they are expressed in several he- 
matopoietic lineages and other tissues (11, 30). Unlike NFATp, 
NFATc is not constitutively expressed in most tissues and cell 
lines analyzed,  but is inducible in lymphocytes by protein 
kinase C (PKC) activators  and/or agents that increase  [Ca2+]i 
(30).  Its distribution  in hematopoietic cell subsets, as well 
as the physiological stimuli that induce its expression, remain 
to be elucidated. 
We have observed that CD16-induced transcription of TNF 
and GM-CSF mRNA in NK cells is abrogated by CsA. This 
data,  coupled with the reported role of NFAT in the tran- 
scriptional regulation of several cytokine genes, led us to ana- 
lyze its expression and regulation in NK cells.  The results 
presented here indicate that CD16 stimulation in human NK 
cells sequentially activates NFATp and induces NFATc mRNA 
accumulation. The former is readily activated from a preformed 
inactive cytoplasmic pool, whereas the latter must be syn- 
thesized de novo: both events occur in a CsA-sensitive manner 
and  require  extracellular  Ca  2+,  but  not  protein  synthesis. 
These data indicate a role for NFATp  and, possibly, NFATc 
in mediating CD16-induced expression of cytokine genes in 
NK cells. 
Materials  and Methods 
Cell Preparations and Stimulation.  The human Jurkat (T lym- 
phoblastoid)  and KPMI 8866 (B lymphoblastoid),  the monkey 
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kidney COS-7, and the murine mAb-producing hybrid B cell lines 
were maintained in culture in R.PMI 1640 medium (BioWhittaker, 
Walkersville, MD) supplemented with 10% heat-inactivated fetal 
bovine serum (Sigma Chemical Co., St. Louis, MO) and 100 #g/ml 
glutamine.  PBL were obtained after density gradient centrifuga- 
tion of venous peripheral blood from healthy individuals. Homo- 
geneous NK cell preparations (:>98% CD16 +/CD56 §  and 
<1% CD3 + cells by indirect immunofluorescence and flow cytom- 
etry) were purified from 10-d cocuhures of PBL with 30 Gy irradi- 
ated RPMI 8866 B lymphoblastoid cells, as described (31). PHA 
blasts were obtained after 5 d culture of PBL (5  x  10  s cells per 
ml culture  medium) with 0.5/~g/ml PHA (PHA-M;  Wellcome 
Diagnostics,  Dartford,  England). 
NK cells (5  x  106/ml) were incubated for the indicated times 
with anti-CD16  mAb or CD16 ligands. The routine  mAb used 
were 3G8 (IgG1, anti-CD16) and B159.5 (IgG1, anti-CD56)  (as- 
citic fluid, final dilution  10 -3) plus 10/~g/ml  goat anti-mouse Ig 
as a cross-linking reagent. Immune complexes (rabbit IgG-sensi- 
tized bovine erythrocytes, EA) were prepared as described (10); non- 
sensitized bovine E were used as controls. Phorbol-12, 13-dibutyrate 
(PDBu; Chemsyn Science Laboratories, Lenexa, KS) and ionomycin 
(Sigma) were used at a 10-7 M and 0.1 #g/ml final concentra- 
tion,  respectively. CsA  (gift  from  Sandoz Pharmaceutics  Inc., 
Vienna, Austria), was used at 100 ng/ml final concentration.  In 
the experiments performed in the presence of the Ca  2+ chelator 
EGTA (1 raM;  Sigma),  1 mM MgCI2 was added. Inhibitors  of 
RNA (actinomycin D [Act D]; Calbiochem, San Diego, CA) and 
protein synthesis (emetine; Sigma) were used at a final concentra- 
tions of 10/zg/ml and 15/zM, respectively. Cells were preincubated 
with the inhibitors for 30 min, and stimulation was performed in 
their  presence for the indicated times. 
Northern Blot Analysis.  Total  cellular RNA was extracted from 
control and stimulated cells (107 per sample) using RNAzol (Bio- 
tex Laboratories, Houston, TX) (10). Northern blot analysis was 
performed using cDNA probes specific for human TNF, GM-CSF, 
and f12 microglobulin (/~2M), as described (8, 9). FuU-length NFATc 
cDNA was provided by Dr. G. Crabtree (Howard Hughes Medical 
Institute, Stanford University, Stanford, CA) and a 2.2-kb Eco-RI 
fragment (nucleotides + 1 to + 2,198) was used as a probe. Integrity 
and amount of RNA loaded per lane were visualized on ethidium 
bromide-stained  gels, and B2M expression was used for normal- 
ization, cDNA probes were labeled with [a32p]dCTP (specific ac- 
tivity = 3,000 Ci/mmol; NEN, DuPont, Boston, MA) by random 
hexamer priming (Random primer kit; Amersham Corp., Arlington 
Heights,  IL). Hybridized bands were visualized on the blots ex- 
posed to X-AR films (Eastman Kodak,  Rochester, NY). 
Nuclear Extracts and Electrophoretic Mobility Shift Assays (EMSA). 
Nuclear extracts were prepared from control and stimulated cells 
as described by McCaffrey et al. (32). Briefly, cells (20 x  106)  were 
washed twice in PBS and resuspended in 400 #1 ice-cold lysis buffer 
(Dignam buffer A [33]: 10 mM Tris, pH 7.4, 10 mM NaC1, 3 mM 
MgC12, 0.1 mM EGTA, 0.5 mM DTT,  1 mM PMSF, 2 #g/ml 
each leupeptin and aprotinin).  After 10 min on ice, 25 #1 of 10% 
NP-40 was added, and the cells were vortexed and centrifuged (4~ 
30 s, 9,000 rpm).  Pelleted nuclei were washed twice in buffer A 
and lysed in 50 #1 Dignam high salt buffer C (20 mM Hepes, pH 
7.9,  420  mM  NaC1, 1.5  mM  MgClz,  0.1  mM  EDTA, 25% 
glycerol, 0.5 mM DTT, 0.5 mM PMSF, 2 #g/ml each leupeptin 
and aprotinin)  (15 min,  4~  After lysis, nuclear extracts were 
centrifuged (12,000 rpm, 10 min, 4~  and the resulting superna- 
tants were diluted (1:1, vol:vol) with Dignam buffer D (20 mM 
Hepes, pH 7.9, 100 mM KC1, 0.1 mM EDTA, 20% glycerol, 0.5 
mM DTT, 0.5 mM PMSF, 2 #g/ml each leupeptin and aprotinin). 
Protein concentration  was determined  using the Bradford colori- metric method (Bio Red Laboratories, Hercules, CA). The extracts 
were used immediately or after storage at  -80~  Hypotonic ex- 
tracts enriched in cytoplasmic proteins were prepared according to 
Jain et al.  (34).  Briefly, cells (2  x  10  ~) were incubated (10 rain 
on ice) in 200 #1 of 7.5 mM Tris buffer, pH 7.6, containing I mM 
MgC12, 0.5 mM DTT, 0.1 mM EDTA, 2 mM PMSF, 20 #g/ml 
each  leupeptin  and aprotinin.  They were then  subjected  to one 
freeze/thaw cycle (dry ice-cooled with 75% ethanol), centrifuged 
(12,000 rpm for 10 min at 4~  and stored at  -80~  until use. 
EMSA reactions  were performed at room temperature in a final 
25-#1vol. Nuclear and, when indicated,  cytoplasmic hypotonic ex- 
tracts (3-7 and 7-10 #g per reaction volume, respectively)  were 
incubated  for  15  min  with  1  #g polyionisine:polycitidilic  acid 
(Boehringer Maunheim Biochemicals, Indianapolis, IN) in binding 
buffer (final concentrations =  8 mM Hepes, pH 7.9, 84 mM NaC1, 
20 mM KC1, 0.3 mM MgCI2, 9% glycerol, 0.04 mM EDTA, 0.2 
mM IYI'T, 0.2 mM PMSF, 0.5 #g/ml each leupeptin and aprotinin). 
After adding 0.5 ng 3zP-labeled probes, the reaction was continued 
for 15 min, stopped with 2 #1 0.1% (wt/vol) bromophenol blue, 
and the samples were electrophoresed  on 5% polyacrylamide gels 
in 0.25x  Tris-buffered EDTA under nondenaturing conditions. Cold 
probes used as competitors were added at the beginning of the reac- 
tion to identical  aliquots  of the extracts.  The Ab used for super- 
shift (antisera, or ascites from mAb, 1:250 final concentration) were 
incubated on ice for 20 min with the nuclear extracts, labeled probes 
were added,  and the reaction continued for 15 min at room tem- 
perature.  Where indicated,  cognate and control peptides  (0.1 #g) 
were preincubated for 30 min on ice with the Ab in the reaction 
mixture without nuclear extracts.  Extracts were then added and 
incubated for 20 min on ice before adding the labeled probe.  The 
anti-NFATp antisera c~72 and c~67.1 and their cognate and control 
peptides have been previously described (29, 35), and the anti-NFATc 
mAb 7A6 (30) was provided by Dr. G. Crabtree (Howard Hughes 
Medical  Institute,  Stanford University).  The Ab used recognize 
both human and murine NFAT. 
Double-stranded synthetic oligonudeotide DNA probes were 
synthesized in the Nucleic Acid Facility  at the Jefferson  Cancer 
Institute (except for the SP1 and AP-1 probes, purchased from Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) and were end-labeled 
with  [3~32p]ATP (specific activity  =  4,500 Ci/mmol;  ICN Bio- 
medicals  Inc.,  Costa  Mesa,  CA) and  T4  polynucleotide kinase 
(Promega Biotech, Madison, WI) according to the manufacturer's 
specifications. After labeling,  free ['),32p]ATP  was removed by cen- 
trifugation on Microspin Sephacryl S-200 HK columns (Pharmacia 
Fine Chemicals,  Piscataway, NJ). The sequences of the oligonucle- 
otide probes used (5' to Y, one strand) are: human Ib2 distal NFAT 
site (NFAT hulb2) (34), GGAGGAAAAACTGTTTCATACAGA- 
AGG; mouse Ib4 NFAT site (NFAT mlL-4) (20,  24),  ATAAAA- 
TTTIECAATGTAAA;  consensus AP-1 site (AP-1), CGCTTGATG- 
ACTCAGCCGGAA; consensus SFI site (SP1), ATICGATCGGTT- 
CGGGGCGAG; human GM-CSF (GM-550, containing an NFAT- 
binding  site)  (17), TCTTATTATGACTCTTGCTTTCCTCCT- 
TTC;  human TNF  (NF-K3,  containing an NFAT-binding  site): 
CAGATGAGCTCATGGGTTTCTCCACC  (19) (used in Fig. 3 A), 
and GAGCTCATGGGTTTCTCCACC (36) (used in Fig.  3 C). 
The NFAT binding sequences in the relevant probes are underlined. 
SDS-PAGE and Western Blot Analysis.  Cells  (5  x  10  +) were 
resuspended  in 30 #1 lysis buffer (40 mM Tris, pH 7.5,  10 mM 
EDTA, 60 mM NaPO4)  plus  an equal volume of 10%  SDS. Ly- 
sates were boiled for 20 min. SDS-PAGE (7.5% acrylamide, reducing 
conditions), Western blot, and enhanced chemiluminescence de- 
tection (Amersham) were done according to standard procedures (7). 
Figure  1.  Effect  of CsA, Ca  2+ chelation, and RNA and protein syn- 
thesis inhibition on CD16-induced accumulation of TNF and GM-CSF 
mRNA. NK cells (30  x  106 per sample) were incubated for 30 min in 
(A) medium without (-) or with (+) 100 ng/ml CsA, or 1 mM EGTA, 
(B) medium without (None) or with CsA, 10 #g/ml Act D, 15 #M eme- 
tine, or a combination of CsA and emetine, as indicated. Medium (B, - ), 
E, or EA (0.5% suspension  final concentration) was added  to each of three 
identical aliquots from the same samples and the incubation  was continued 
for 2 h. Cells were washed and total KNA was extracted and size fraction- 
ated in a 1% agarose  denaturing gel. Northern blot analysis  was performed 
using TNF and GM-CSF (top)  or B2M (A, bottom)  random primer-labeled 
cDNA probes, as described in Materials and Methods. Ethiduim bromide 
staining of the corresponding gel is shown in R 
Resulu 
CsA Sensitivity of CD16-ind~ed Cytokine mRNA ~cumu- 
lation.  TNF and GM-CSF mKNA are induced to accumu- 
late in NK cells stimulated for 2 h with immune complexes 
(EA)  (Fig.  1 A)  or anti-CD16 mAb (reference  9  and  data 
not  shown).  This  effect is  abolished upon chelation  of ex- 
Figure  2.  NFAT  activation in NK cells upon CD16 stimulation. (A) 
NK cells (5  x  106/ml, 107 per sample) were incubated for I h in medium 
without  (None) or with  ascites (10 -3 final dilution) of mAb B159.5 
(CD56,  control)  or  3G8  (CD16),  each with  added 10  #g/m1  goat 
anti-mouse as cross-linker; E or EA (each 0.5% suspension final concen- 
tration); or 10-~ M PDBu plus 0.1/zg/ml ionomycin (P/l), as indicated. 
(B) Cells were incubated for 30 min in medium without  (-) or with 
(+) CsA or EGTA, as in Fig. 1. Medium (None), E, or EA were then 
added to each of I0r cell aliquots and the incubation was continued for 
1 h. Nuclear extracts were prepared and NFAT activation was assessed 
by EMSA (3/~g protein per lane) in 5% acrylamide nondenaturing gels 
using a 32p-labeled dsDNA oligonucleotide probe corresponding to the 
distal NFAT  site of  the human II+-2  promotor (NFAT  hulb2), as described 
in Materials and Methods. 
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identical aliquots of nuclear extracts (5/~g proteins per lane) from NK 
cells stimulated for 1 h with EA were incubated without  (None), with 
25- and 100-fold (A), or 80-fold molar excess (B) of the indicated cold 
dsDNA oligonucleotides  before adding the labeled NFAT hulb2 probe. 
(C) Identical aliquots of  nuclear extracts (3/xg proteins per lane)  prepared 
from NK cells cultured for 1 h in medium alone (None), E, or EA added, 
as indicated, were assayed  for binding to the NFAT  site in the human TNF 
promoter using the NF-k3 probe. The sample from EA-stimulated cells 
was also incubated in the absence (None) or presence of 100-fold  molar 
excess of the listed cold double-stranded DNA oligonncleotides before 
adding the 32P-labeled  NF-K3 probe. NFAT, the shift caused by binding 
of the factor to the probe; FP, the position of the unbound/free probe; 
p, probe alone. The appearance  of two lower bands in the presence  of  both 
specific and non specific  competitors likely represents artefactual  binding 
of proteins in the extracts, when the majority of specific  factors has been 
competed by the excess of the corresponding probe. 
tracdlular  Ca  2+,  in agreement  with  our previous data  (8), 
or pretreatment of the cells with CsA. Accumulation of GM- 
CSF mRNA  induced upon CD16  stimulation,  like that of 
TNF (8), depends on induced gene transcription  and is in- 
hibited in cells pretreated with Act D  (Fig.  1 B).  Pretreat- 
ment of the ceils with protein synthesis inhibitors resulted 
in overexpression of CD16-induced TNF and only minimal 
inhibition of GM-CSF mRNA  accumulation under condi- 
tions in which the inhibitory effect of CsA was still evident. 
These results indicate that CD16-induced transcription of these 
genes involves activation of a CsA-sensitive, Ca2+-dependent 
Figure 4.  Kinetics  of NFAT activation  in CD16-stimulated human NK 
cells. Nuclear extracts  were prepared  from NK cells  incubated for the indi- 
cated times in medium without (None) or with EA. They were analyzed 
by EMSA using the NFAT mlL-4 (top  panel) and the AP-1 probe (bottom 
panel). The shifts  due to NFAT  and AP-1  binding to the probes  are indicated. 
pathway using dements  constitutively present in NK cells. 
CD16.induced Activation of  NFAT.  To determine whether 
NFAT is expressed in NK cells and is activated upon CD16 
stimulation, we performed EMSA with nuclear extracts from 
CD16-stimulated  cells  and  oligonucleotide  probes  corre- 
sponding  to  the conserved NFAT distal binding  sequences 
in t~he human  II.,2,  the murine  I1.,4,  and the human TNF 
and GM-CSF promoters. Binding of NFAT to the first probe 
depends on its association with AP-1 (34, 37), whereas that 
to the IL-4 probe is independent of other factors (20). Stimu- 
lation of NK cells with anti-CD16 mAb, immune complexes, 
or PDBu/ionomycin for 1 h  activated NFAT, detected with 
the NFAT hulL-2 probe (Fig. 2 A). Immune complex- (Fig. 
2 B) and anti-CD16 mAb- (not shown) induced activation 
was  prevented chelating  extracellular  Ca  2+ with  EGTA  or 
pretreating  the ceils with  CsA. 
The  complex  activated  by  CD16  was  efficiently  and 
specifically competed (Fig. 3 A) by the NFAT hulL-2, by each 
of two other cold oligonucleotides containing NFAT binding 
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activation. NK cells (6 x  107 per sample) were incubated  without (None) 
or with emetine  for 30 min, after  which identical  107 cell aliquots were 
incubated for the indicated  times  in medium  without (None) or with E 
or EA, as described  in Fig. 2. Nuclear  extracts  were  prepared  and analyzed 
by EMSA with the NFAT miD4 probe. The shift resulting  from NFAT 
is indicated. 
sequences in the promoters of cytokines produced by NK cells 
(GM-550 from the GM-CSF/ID3 enhancer [17] and NF-g3 
from the TNF promoter [19]), but not by SP1 (containing 
an unrelated sequence),  and by excess cold oligonucleotides 
corresponding to an additional NFAT binding sequence (NFAT 
miD4) or to the AP-1 binding sequence (Fig. 3 B). In EMSA 
performed with the labeled NF-g3 oligonucleotide (Fig.  3 
C), a shift was detected that was inhibited by all cold oligo- 
nucleotides used that contain NFAT binding sites (NF-g3, 
NFAT hulL-2, and mll_,4), but not by SP1. Similar results 
were obtained with the labeled GM-550 oligonudeotide (not 
shown). Thus, CD16-induced transcription of  TNF and GM- 
CSF correlates with activation of NFAT, the NFAT expressed 
in NK and T  cells have identical DNA binding specificity, 
and DNA binding activity of  both is enhanced upon associa- 
tion with AP-1. 
Protein Synthesis Requirement  for CD16-induced NFAT Acti- 
vation.  NFAT activation was detected with the NFAT mlL-4 
(Fig. 4, top) and the NFAT hulL-2, AP-l-dependent, probe 
(not shown) within 15 min stimulation of CD16, and it was 
sustained up to 2 h. AP-1 in nuclear extracts from CD16- 
stimulated NK cells contributed to the observed NFAT binding 
to the NFAT hulL-2 probe (Fig. 3 B ); therefore, we analyzed 
the in vitro AP-1  activity in the same samples.  In nuclear 
extracts from the NK cells used here,  AP-1 was detectable 
by EMSA before addition of any stimulus (time 0).  CD16 
stimulation induced AP-1 activity higher than background 
within 30 min and sustained up to 2 h (Fig. 4, bottom). These 
data indicate that NFAT activation is an early step in the CD16 
activation pathway and involves two components detectable 
in vitro: activation of NFAT on its own and increased AP-1 
activity. 
To test the hypothesis that the factor(s) involved in cytokine 
gene transcription regulated by CD16  stimulation is (are) 
directly activated from a preformed pool, we analyzed CD16- 
induced NFAT activation in the absence of de novo protein 
synthesis. NFAT activation in NK cells pretreated with eme- 
tine (Fig.  5) was sustained throughout the 2-h stimulation 
with Fc'yRIII ligands, as assessed in EMSA using the AP- 
1-independent NFAT mlL-4 probe.  NFAT activity detected 
Figure 6.  Detection  of  NFAT  in cytoplasmic  extracts  of  nonstimulated 
NK cells. (A) Identical  aliquots  of cytoplasmic  extracts from nonstimu- 
lated NK cells (7/zg per sample) were analyzed  by EMSA with NFAT 
mlL-4  and NFAT  hulb2 oligonudeotide  probes, as indicated.  The specificity 
of the shift was assessed for each probe by competition  with a 100-fold 
molar  excess  of NFAT  (huIb2 and mIL-4)  cold  probes, cold  SP1, and AP-1, 
as indicated; --, no cold  oligonucleotide  added.  (B) EMSA  were  performed 
with nuclear  extracts (N, 3/~g per lane) from nonstimulated  cells, cyto- 
plasmic extracts (C, 7/~g per lane) from the same cells, or a mixture  of 
both (N+ C). Identical  aliquot  s of  the mixture  of  cytoplasmic  and nuclear 
extracts  were  incubated  without  (-) or with a 100-fold  molar  excess  NFAT 
huIb2 or AP-1 cold  oligonucleotides,  as indicated,  to assess  DNA binding 
specificity  and AP-1 dependence.  The shift  resulting  from NFAT  binding 
to the probes and the position of free probes are indicated. 
within 30 rain was not affected by the inhibitor, but it was 
reproducibly decreased compared to controls after 2-h stim- 
ulation in the presence of emetine, possibly reflecting the dis- 
appearence and lack of replacement of the endogenous NFAT 
pool in the absence  of protein synthesis. 
Expression of Cytoplasmic NFAT  in  Nonstimulated  NK 
Cells.  To determine directly whether CD16 stimulation ac- 
tivates  a preformed NFAT pool in nonstimulated NK cells 
and induces its translocation to the nucleus, we analyzed the 
presence of NFAT in cytosolic extracts of nonstimulated NK 
cells. The NFAT mlL-4 probe detected NFAT in cytoplasmic 
extracts from these cells (Fig. 6 A), and DNA binding was 
inhibited by an excess of the same cold probe, but not by 
the AP-l-dependent NFAT hulD2 or the AP-1 oligonucleo- 
tides. As expected, cytoplasmic NFAT was not detectable using 
the NFAT hulL-2 probe (Fig. 6 A, right panel). A band with 
mobility faster than that of the NFAT complex was observed 
with this probe in the cytoplasmic extracts, was not com- 
peted with excess cold probe and is likely caused by nonspecific 
binding. NFAT binding to the NFAT huIL-2 probe was recon- 
stituted (Fig. 6 B, lane N + C) when the cytoplasmic extracts 
(lane C) were combined with nuclear extracts (lane N), con- 
taining AP-1 (Fig. 2 and data not shown) but not NFAT (Fig. 
6 B,  lane N),  prepared from the same nonstimulated NK 
cells. Both cold AP-1 and NFAT huIb2 oligonudeotides, but 
not unrelated oligonucleotides (not shown), efficiently in- 
hibited NFAT binding to the probe. 
NFATp and NFATc Expression and Activation in NK Cells. 
805  Aramburu  et al. Figure 7.  Identification  of NFATp in NK cells. (A) Nuclear extracts 
from NK cells, incubated in medium without (None) or with EA for 1 h, 
were analyzed for the presence of NFATp and NFATc using specific anti- 
bodies and EMSA in supershift assays. Before adding the labeled NFAT 
mlL-4 probe, identical aliquots of the samples (3 ttg per lane) were in- 
cubated for 15 min without (-) or with NRS, mAb B159.5, IgG1 (CD56), 
anti-NFATp rabbit antiserum (c~72), anti-NFATc mAb, IgG1 (7A6), or 
anti-NFATp plus anti-NFATc  antibodies (c~72 +  7A6). In the right panel, 
NFATp  c~72 antiserum, preincubated (30 min, 4oC) in medium alone (-), 
with its cognate peptide (p72) or an irrelevant peptide (p25), was added 
to identical aliquots  (3/zg per lane) of a nuclear extract  from  1-h EA- 
stimulated NK cells, and the samples were analyzed by EMSA and super- 
shift as described in Materials and Methods.  The first two lanes are ali- 
quots from the same nuclear extract preincubated with no antiserum (-) 
or with a NRS, respectively, and no peptide. (B) Identical aliquots (3/~g 
per lane) of a nuclear extract from 2  x  107 4-h PDBu plus ionomycin 
(P/I)-stimulated Jurkat cells were pretreated with each of the same anti- 
bodies as in A and subjected to EMSA. Antibodies were used at a final 
dilution of 1/250 from the original serum (rabbit) or ascitic fluid (mouse); 
peptides were used at 4/~g/ml final concentrations.  NFAT binding to the 
NFAT mlL-4 probe and the supershift induced in the presence of the Ab 
are indicated with closed and open arrowheads,  respectively. 
Two related but distinct proteins, NFATp and NFATc, mediate 
NFAT binding activity (29, 30). To analyze the relative con- 
tribution of these elements to the NFAT activity in CD16- 
stimulated NK cells, we used an antiserum against the mu- 
rine NFATp peptide 72 (amino acids 206-232) (29), as well as 
an mAb to the human NFATc (mAb 7A6) (30) in supershift 
experiments. Most of the NFAT complex detected with the 
NFAT miD4 probe in nuclear extracts from 1-h CD16-stimu- 
luted NK cells was supershifted by the anti-NFATp antibody 
(Fig. 7 A). Similar results were obtained using anti-NFATp 
antiserum c~67.1 (35) and nuclear extracts from 30-min and 
2-h CD16-stimulated  NK cells (not shown). An irrelevant 
antiserum (nonimmune rabbit serum INKS]) and an isotype- 
matched anti-CD56 mAb did not affect the relative mobility 
of the complex, and none of the antibodies bound the DNA 
probe alone (not shown). The supershift induced by the anti- 
NFATp antibody was specifically prevented by the cognate 
peptide 72, but not by a different peptide (peptide 25, amino 
acids 685-703  in the murine NFATp) (29). The anti-NFATc 
mAb 7A6 induced no detectable supershift (Fig. 7 A), nor 
did it increase  the amount of supershifted  complex when com- 
bined with the ot72 Ab. Consistent with these results, NFATc 
was detected neither in nuclear extracts from short-term stimu- 
lated cells nor in cytosolic preparations of nonstimulated or 
4-h stimulated NK cells (not shown). On the contrary (Fig. 
Figure 8.  Biochemical characteristics of NK cell NFATp. Whole-cell 
lysates from PHA blasts (7"}, NK, or COS-7 cells were resolved in SDS- 
PAGE (7.5% acrylamide, reducing conditions). Western blot analysis  was 
performed with the anti-NFATp  rabbit antiserum ot67.1 (/efipanel,  otNFATp) 
and a nonimmune  rabbit serum (right  panel, NRS)  as control, followed 
by ECL detection, as described in Materials and Methods. The T and NK 
cell samples were from 2  x  106 cells, the COS cell sample was from 106 
cells; antisera were used at a 2  x  10 -3 final dilution. Positions of molec- 
ular size markers are indicated. 
7 B), the anti-NFATc  mAb efficiently supershifted the NFAT 
complex in nuclear extracts from Jurkat cells or from PHA 
lymphoblasts  (not shown) stimulated  for 4 h with PDBu/ 
ionomycin, conditions in which NFATc  is induced and acti- 
vated in these cells (30). Only a small portion of the complex 
was supershifted by the anti-NFATp antibody in the Jurkat 
T cell line. These results confirm that the antibodies do not 
detect cross-reactive determinants in the two NFATp. 
SDS-PAGE of total lysates from non stimulated  NK cells 
followed by Western blot analysis with the anti-NFATp an- 
tiserum ot67.1 resolved a specific prominent band of "~120 
kD (Fig. 8),  similar in size and relative density to that de- 
tected in PHA blast lysates, and corresponding to the phos- 
phorylated (cytoplasmic) form of NFATp (35). Bands with 
lower relative molecular weight detected in both the NK and 
T cell lysates  likely  represent partially dephosphorylated NFATp 
and/or their degradation  products. 
Consistent with the results from EMSA, NFATc  mRNA 
was undetectable in nonstimulated NK cells (Fig. 9), but it 
accumulated at levels significantly higher than background 
within 2-h stimulation with CD16 ligands. Induction of its 
expression was, as previously reported (30), CsA-sensitive, 
and it did not depend on de novo protein synthesis, but de- 
pended on RNA synthesis. 
To determine whether newly synthesized  NFATc  contributes 
to the NFAT activity observed at later times after CD16 stim- 
ulation, we analyzed its presence in cytoplasmic and nuclear 
extracts from NK cells by EMSA. NFATc  protein was unde- 
tectable in nonstimulated cells and in cells stimulated up to 
4 h with immune complexes or a combination of phorbol 
esters and a Ca  2+  ionophore.  The anti-NFATc Ab induced 
supershift when added to nuclear extracts from phorbol ester 
and ionomycin-treated PHA lymphoblasts andJurkat T cells, 
but not when added to NK cell extracts  (not shown). 
806  NFAT Activation in NK Cells Figure  9.  Expression  of  NFATc  mRNA in CD16-stimulated  NK cells. 
NK cells, 4  x  107 per sample, were  incubated for 30 min in medium 
without (None) or with Act D, emetine,  and CsA, as described  in Fig. 
1. Medium  (-), E, or EA was added  to identical 107 cell aliquots of the 
samples and incubation  was continued  for 2 h. Total RNA was then ex- 
tracted, run in 1% agarose  denaturing gel, and Northern blot analysis 
was performed  using  a human  NFATc  random  primer-hbeled  eDNA  probe 
(top  pand). After  stripping, the same  blot was hybridized  to the ~2M cDNA 
(bottom  panel) to control amounts  of RNA loaded  per lane. Positions of 
18 and 28 S mRNA are indicated. 
Discussion 
The results presented here demonstrate that NFAT is ex- 
pressed in NK cells. Stimulation of these cells with immune 
complexes not only results in activation and nuclear translo- 
cation of a preexisting cytoplasmic NFATp component iden- 
tical  to  that  present  in  T  cells,  but  also  induces de novo 
expression of NFATc mRNA, and the former NFAT is func- 
tionally active in regulating cytokine gene expression. The 
use of homogeneous NK cell preparations with no detect- 
able T cell contaminants and of stimuli that do not activate 
T  lymphocytes (10) exclude the participation  of T  cells in 
the observed effects. 
Fc3,RIIIA ligands and cytokines, e.g., Ib2 and IL-12, in- 
duce transcription of cytokine genes in NK cells. The 11,2- 
and  IL-12-induced transcription  is  Ca  2+  independent  (8); 
that induced upon Fc3'R stimulation is Ca  2+ dependent (8). 
Our results demonstrate that TNF and GM-CSF (like IFN-y 
and c-myc, not shown) expression is induced upon CD16 stim- 
ulation in a CsA-sensitive fashion, independent of  protein syn- 
thesis,  indicating that the effect of both CD16  stimulation 
and CsA occur at the level of preexisting elements in NK 
cells.  These data add to previous observations indicating a 
similarity at the molecular and signal transduction levels be- 
tween CD16 and the TCR and slg complexes on T  and B 
lymphocytes  (38,  39),  where  the  Ca2+-dependent,  CsA- 
sensitive factor NFAT is involved in antigen receptor-mediated 
gene transcription.  In T  cells NFAT regulates transcription 
of I1,2, I1,3,  Ib4, GM-CSF, and TNF genes (11, 16, 17, 19, 
20, 40). Among these genes, at least TNF appears to be simi- 
larly regulated in B cells,  where NFAT is transcriptionally 
active (26-28,  41). 
In NK cells,  ligation  of FcyR.III with  specific  mAb or 
Ag-Ab complexes, its physiologic ligand, activates a nuclear 
factor that has the same DNA binding specificity as NFAT; 
this activation, like that of the CD16-induced cytokines, is 
CsA sensitive and Ca  2+ dependent. Instead,  Ca2+-indepen - 
dent signals transduced by cytokines (I1,2) that induce TNF 
and GM-CSF expression do not mediate NFAT activation 
(not  shown),  suggesting  that  CD16  specifically  engages 
Ca2+-dependent,  CsA-sensitive  elements. Nuclear extracts of 
CD16-stimulated NK cells contain protein(s) that bind spe- 
cifically NFAT binding  sequences present in  the enhancer 
regions of the promoters of several cytokines produced by 
NK cells,  e.g.,  TNF,  GM-CSF,  and I1,3  (16,  17,  19),  and 
these same sequences compete specifically, and as efficiently 
as those contained in the II,2 and I1,4 promoters, for NFAT 
binding to the distal NFAT I1,2 binding site present in the 
oligonudeotides used in the EMSA. This indicates that NK 
cell NFAT has DNA binding specificity identical to that of 
its T and B cell counterparts (11, 26, 27, 42), and it supports 
a critical role for NFAT in NK cell transcriptional regulation 
of these cytokines. The same data, however, do not exclude 
the participation of other as yet not identified components 
in the transcriptional activation of cytokine genes in NK cells, 
analogous to the necessary, but not sufficient, role of NFAT 
in the transcriptional activation of the IL-2 gene promoter 
in T  cells  (43). 
NK cells NFAT can associate with AP-1, as established using 
the huI1,2 NFAT site. NFAT binding to this element requires 
a nuclear component newly synthesized in a PKC-dependent 
fashion (38, 44, 45). This component contains AP-1, which 
is formed by various combinations ofjun orjun-fos polypep- 
tides (45,  46).  NFATp-AP-1  interaction results in increased 
NFATp DNA binding and transcriptional capacity at the rec- 
ognition sites in the I1,2 promoter and in at least one NFAT 
site (CLEO) of the GM-CSF promoter (11, 25).  AP-1 oligo- 
nucleotides inhibited binding of NK cell NFATp to the NFAT 
huI1,2 probe, proving that the factor can associate with AP-1. 
In the NK cells used here, EMSA revealed significant levels 
of AP-1  activity, and Fc'yRIII stimulation increased/main- 
tained this activity for prolonged periods of time. Northern 
blot analysis revealed expression of c-jun andjun-D but not 
jun-B or c-fis before stimulation (not shown), suggesting that 
complexes containing c-jun andjun-D,  known to compose 
AP-1 (45),  are preformed in these cells and contribute to the 
constitutive AP-1 activity. CD16 stimulation also induces c-fis 
mRNA accumulation within 20 rain (not shown), which may 
contribute to the sustained AP-1 levels observed after stimu- 
lation.  Inhibition of AP-1  synthesis and/or lack of replace- 
ment of NFATp with newly synthesized protein might ac- 
count, at least in part, for the decreased NFAT levels at later 
times after stimulation in the absence of protein synthesis. 
Kinetics of induction of the AP-l-dependent NFAT activity 
in freshly purified NK cells,  however, may not correspond 
to that reported here, where constitutive AP-1 activity likely 
reflects previous activation of the cells in the culture system 
used to obtain large numbers of polyclonal NK cell popula- 
tions. Although phenotypically and functionally equivalent 
to NK cells freshly separated from peripheral blood (31), the 
short-term cultured NK cells revert to a resting state after 
activation/proliferation in culture, and they respond to several 
stimuli proliferating and/or producing cytokines with faster 
kinetics than resting, non-previously activated cells (31, 47). 
Cytoplasmic extracts from nonstimulated NK ceils con- 
tain NFAT, but not AP-1 or AP-l-dependent NFAT activity, 
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sence of AP-1 in these extracts also serves to exclude possible 
artefacts due to contamination with nuclear material. NFAT 
was detected in cytosolic extracts of NK cells using the mlb4 
NFAT probe, to which it can bind in the absence of addi- 
tional factors. AP-l-dependent NFAT activity detected with 
the hulL,2 probe was reconstituted when nuclear extracts from 
nonstimulated cells containing no NFAT activity but ex- 
pressing AP-1 were combined with cytoplasmic preparations 
from the same cells, indicating association  of cytoplasmic 
NFAT with nuclear AP-1, and supporting the hypothesis that 
NFAT activation in NK cells results in its translocation to 
the nucleus, as reported in T lymphocytes. These data indi- 
cate that cytoplasmic NFATp is preexistent in NK cells, as 
confirmed  by its identification in nonstimulated cells as a pro- 
tein with antigenic and biochemical characteristics indistin- 
guishable from those of the cytoplasmic, phosphorylated form 
of NFATp (35). 
NFATp belongs to a family of factors that include NFATc 
(30) and the recently cloned NFATx (47), all sharing significant 
homology, identical DNA binding specificity, and capable 
of associating with AP-1 (29, 30, 47). NFATx mKNA is ex- 
pressed preferentially  in the thymus and at very low levels 
in peripheral leukoeytes.  NFATc expression is inducible by 
PKC activators in human T cell lines, as well as splenic and 
thymic cells (30). NFATc mRNA is undetectable in nonstimu- 
lated NK cells, but is induced in a CsA-sensitive fashion after 
a 2-h stimulation with Fc3'R ligands (Fig. 9) or phorbol esters 
(not shown). These data for primary NK cells extend results 
reported using T cell lines. Expression of NFATc mRNA is 
detectable in emetine-treated cells, but not in the absence of 
de  novo RNA  synthesis,  suggesting that  CD16-induced 
NFATc expression occurs via a mechanism that includes di- 
rect or indirect induction of gene transcription, independent 
from newly synthesized proteins. 
Despite the fact that NFATc mRNA was inducible in NK 
cells, we did not detect NFATc  protein, and the NFATc-specific 
mAb did not induce supershift in nuclear (Fig.  7) or cyto- 
solic (not shown) extracts from 1-h stimulated NK cells. How- 
ever, the same mAb supershifted the NFAT detected in the 
Jurkat cell line and in phorbol ester- and ionomycin-stimulated 
PHA lymphoblasts (not shown), where the combination of 
both anti-NFATp and anti-NFATc antibodies supershifted vir- 
tually all the complex. Several possibilities  may account for 
the inability of the anti-NFATc mAb to detect this molecule 
in NK cells. Based on the observations that NFATc isoforms 
exist  (Crabtree,  G., personal communication) and may be 
differentially expressed in distinct hematopoietic cell lineages, 
and that the supershift induced by the anti-NFATp antibodies 
is incomplete, the most likely explanation for these results 
is that an NFATc isoform or NFAT spedes different from that 
detected by the mAb used here is/are expressed in NK cells. 
Other possibilities  indude that the epitope detected by the 
antibody is masked by a protein(s) absent in T cells but present 
in NK cells, or that the NFATc mRNA transcript induced 
in NK cells is nonproductive. However, both possibilities are 
unlikely because (a) the anti-NFATc mAb supershifted the 
same amount of NFATc in Jurkat cell extracts  when tested 
either separately or mixed with an excess nuclear extract from 
CD16-stimulated NK cells, where NFATc was undetectable 
(not shown); and (b) the size of the NFATc mKNA in NK 
cells is identical to that in T lymphocytes and corresponds 
to that reported for a productive transcript (30). 
Our results indicate that NFATp is the most relevant,  if 
not the only, protein included in the NFAT complexes de- 
tected in NK cells at early times after CD16 stimulation. The 
relative amount of NFATp supershifted varied (60-90%) in 
experiments repeated with individual nuclear extracts,  sug- 
gesting that interexperimental variability may account, in part, 
for the incomplete supershift. However, the presence of re- 
sidual NFAT not supershifted by the available anti-NFATp 
and -NFATc antibodies may reflect the participation of addi- 
tional factors  (e.g.,  NFATx or new family members) with 
DNA binding specificity overlapping with that of NFATp. 
Our data support the conclusion that CD16 stimulation in 
NK cells induces NFATp activation that likely promotes, in 
a CsA-sensitive and possibly calcineurin A-dependent fashion, 
translocation to the nucleus of a preexistent NFATp, iden- 
tical to that predominant in T cells, although formal proof 
of the latter awaits nucleotide sequence comparison. They 
confirm  that  the  NFATp  cytoplasmic component is  not 
specifically and exclusively expressed in T lymphocytes, and 
they serve to further generalize  this conclusion to all lym- 
phoid and, possibly, most hematopoietic cell types. In this 
regard,  it  will be interesting to determine whether Ab- 
independent target cell recognition by NK cells, which results 
in Ca2+-dependent activation of cytokine genes via a mech- 
anism at least in part distinct from that induced via FeyRIIIA 
(49, 50), can activate NFATp, and which physiologic stimuli 
are involved in NFAT activation in antigen-presenting cells, 
e. g., monocytes (11). The significance of NFATc mRNA in- 
duction in NK cells, and the possibility that new species of 
the NFAT family are expressed in these cells, awaits further 
study. Generation of additional antibodies to NFATp and 
NFATc isoforms and/or, possibly, other NFAT species will 
help to address the question of the relative contribution of 
NFAT members to gene expression,  not only in NK cells, 
but also in other immune cell types. 
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